This article first appeared on GuruFocus.
SPY led the ETF selling in AbbVie (ABBV) on Thursday, as ETF activity produced a net outflow of $62.0 million. More funds traded the other way 40 ETFs bought while 16 sold but in smaller amounts. The move followed two straight days of net buying, with $68.8 million added on Nov. 11 and $33.5 million on Nov. 10. Before that, ETFs were net sellers of $4.3 million on Nov. 9 and $5.6 million on Nov. 6.
Every ETF and guru trade in ABBV is tracked on the ABBV guru trades page.
Which ETFs sold ABBV on Thursday?
The largest sellers by dollar value were SPY ($48.7 million), XLV ($23.0 million) and IVE ($10.2 million). In all, 40 ETFs added shares and 16 cut them.
SPY accounted for the largest share of the selling, cutting 165,402 shares for a $48.7 million reduction, with its stake down 0.76% to 21,610,262 shares at a 0.8% weight. XLV shed 78,144 shares worth $23.0 million, trimming its position 0.6% to 13,047,705 shares at a 7.66% weight. IVE sold 34,500 shares for $10.2 million, CGCV cut 19,776 shares for $5.8 million, and IVV reduced 12,312 shares for $3.6 million. AbbVie is a Healthcare company in the Drug Manufacturers – General industry with a market cap of $521.5 billion.
Have ETFs been buying or selling ABBV lately?
Over the last 5 reported days, ETFs were net buyers on 2 and net sellers on 3, so the recent trend is mostly selling.
What does ABBV do?
AbbVie is a global, diversified research-based biopharmaceutical company that operates as a single segment dedicated to discovering, developing, manufacturing, and commercializing innovative medicines.
AbbVie reported trailing-12-month revenue of $66.01 billion, up 10.6% over one year, with gross and net margins of 73.7% and 15.7%. Its P/E ratio is 50.78 and its P/S ratio is 7.92. The company has a GF Score of 74, and its GF Value of $229.72 compares with a price of $295.03. AbbVie pays a dividend yield of 2.27% and has returned 32.99% year to date.
